Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Bone; Disorder, Development and Growth
Interventions: Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Pain Related to TMD
Interventions: THOR® laser system; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Weight Gain
Interventions: Exenatide, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chemotherapeutic Agent Toxicity, Multiple Myeloma, Peripheral Neuropathy
Interventions: glutamine, quality-of-life assessment, placebo; Drug · Other
Lead sponsor: Beth Faiman; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol higher volume, Placebo lower volume, Placebo higher volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 3 Days to 6 Days
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 11
States / cities: New Haven, Connecticut • Indianapolis, Indiana • Detroit, Michigan + 7 more

Conditions: Glaucoma
Interventions: rhNGF, Vehicle; Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Osteoarthritis of the Knee
Interventions: HLXL; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 40 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Lithium Carbonate, Riluzole, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 19 more

Conditions: Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation
Interventions: dapagliflozin, Placebo; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
Interventions: Active delta-9-THC, Placebo, Active Ethanol; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Hypogammaglobulinemia, Congenital Heart Disease
Interventions: IVIG, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Up to 6 Months
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Laparoscopic Cholecystectomy
Interventions: 2 capsules Oral Tylenol 2000 mg and IV "salt water", IV tylenol 1000mg and 2 oral capsule "sugar pills"; Drug
Lead sponsor: Defense and Veterans Center for Integrative Pain Management; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Fort Bragg, North Carolina

Conditions: Colorectal Cancer, Coffee, Gastrointestinal Microbiome, Stenosis, Fibrosis, Liver, Ultrasound Elastography, Proton Magnetic Resonance Spectroscopy
Interventions: Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule., Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postoperative Chylothorax, Congenital Heart Disease, Open Heart Surgery, Chylothorax
Interventions: Propranolol Hydrochloride, Placebo; Drug
Lead sponsor: June Wu; Other
Eligibility: 7 Days to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Fecal Microbiota Transplant (FMT), Placebo; Biological
Lead sponsor: Stacy A. Kahn; Other
Eligibility: 5 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cannabis, Psychotic Disorders
Interventions: THC, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 35 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Human Immunodeficiency Virus
Interventions: Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 36
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 33 more

Conditions: Ulcerative Colitis
Interventions: NX-13 250mg, NX-13 750mg, NX-13 Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Miami, Florida • Orlando, Florida • Tampa, Florida + 8 more

Conditions: The Frailty Syndrome
Interventions: Ghrelin Group 1, Ghrelin Group 2; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 70 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chordoma
Interventions: Placebo, GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph; Other · Biological · Radiation + 1 more
Lead sponsor: NantCell, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Hyperpolarized Helium-3, Placebo, Aformoterol; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 50 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation
Interventions: AVTX-801, Placebo; Drug
Lead sponsor: Eva Morava-Kozicz; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

Photobiomodulation for Management of Temporomandibular Disorder Pain

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee

Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

Post-bypass Prophylactic IVIG in Infants and Neonates

Comparing Effectiveness of IV vs Oral Acetaminophen Given Perioperatively for Lap Choles for Pain Control,

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

Propranolol Treatment for Postoperative Chylothorax

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

Cannabinoids and Cerebellar-Motor Functioning

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

Ghrelin Dose Finding In Frail Elderly

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI

Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801)